EGFR and neoplasm: To this end, lipid-based nanoparticles, solid lipid nanoparticles, or polymer–lipid hybrid nanocarriers may be co-functionalized with raft-targeting moieties (e.g., cholesterol-binding peptides, anti-Cav-1, or anti-flotillin antibody fragments) and CRC-associated targeting ligands (such as carcinoembryonic antigen, chondroitin sulfate, tumor-homing peptides, RGD peptides, or the EGFR-binding peptide GE11), whose receptors exhibit low or negligible expression in normal cells but are highly expressed in CRC [83].